These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 27772764

  • 1. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y, Wang Q, Ren HT, Qiao L, Zhang Y, Fei YY, Zhao Y, Cui LY.
    J Neurol Sci; 2016 Nov 15; 370():224-228. PubMed ID: 27772764
    [Abstract] [Full Text] [Related]

  • 2. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder.
    Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, Lian Z, Feng H, Miao X, Zhou H.
    Eur J Neurol; 2017 Jan 15; 24(1):219-226. PubMed ID: 27783452
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis.
    Ma J, Yu H, Wang H, Zhang X, Feng K.
    J Neuroimmunol; 2022 Feb 15; 363():577790. PubMed ID: 34959021
    [Abstract] [Full Text] [Related]

  • 4. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder.
    Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG.
    J Neurol Sci; 2018 Feb 15; 385():192-197. PubMed ID: 29406904
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.
    Espiritu AI, Pasco PMD.
    Mult Scler Relat Disord; 2019 Aug 15; 33():22-32. PubMed ID: 31136907
    [Abstract] [Full Text] [Related]

  • 6. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, Zhou H.
    Clin Neuropharmacol; 2016 Aug 15; 39(2):81-7. PubMed ID: 26818042
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of modified reduced-dose rituximab in Chinese patients with neuromyelitis optica spectrum disorder: A retrospective cohort study.
    Cao S, Yu H, Tian J, Li Y, Shen Y, Ji X, Wang X, Zhou X, Gu Y, Zhu F, Duan X, Xiao X, Fang Q, Chen X, Xue Q.
    J Neurol Sci; 2021 Oct 15; 429():117616. PubMed ID: 34450520
    [Abstract] [Full Text] [Related]

  • 8. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder.
    Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, Kim BJ, Kim HJ.
    JAMA Neurol; 2014 Nov 15; 71(11):1372-8. PubMed ID: 25199960
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder.
    Huang W, Wang L, Xia J, Li W, Wang M, Yu J, Li Q, Wang B, Pan J, Du L, Ma J, Tan H, Chang X, Lu C, Zhao C, Lu J, Zhou L, ZhangBao J, Quan C, Pan-Yangtze River Delta Alliance for Demyelinating Disease.
    Eur J Neurol; 2022 Aug 15; 29(8):2343-2354. PubMed ID: 35398950
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors.
    Zhang L, Tian J, Dong X, Jia Z, Sun Y, Guo L, Tan G, Li B.
    Neurol Sci; 2022 Apr 15; 43(4):2651-2658. PubMed ID: 34585292
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of efficacy and tolerability of first-line therapies in NMOSD.
    Poupart J, Giovannelli J, Deschamps R, Audoin B, Ciron J, Maillart E, Papeix C, Collongues N, Bourre B, Cohen M, Wiertlewski S, Outteryck O, Laplaud D, Vukusic S, Marignier R, Zephir H, NOMADMUS study group.
    Neurology; 2020 Apr 14; 94(15):e1645-e1656. PubMed ID: 32170036
    [Abstract] [Full Text] [Related]

  • 12. Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study.
    Shi Z, Du Q, Chen H, Zhang Y, Qiu Y, Zhao Z, Wang J, Yan C, Zhang Q, Yang M, Zhou H.
    J Neurol; 2020 Apr 14; 267(4):913-924. PubMed ID: 31776721
    [Abstract] [Full Text] [Related]

  • 13. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
    Pathomrattanapiban C, Tisavipat N, Jitprapaikulsan J, Prayoonwiwat N, Rattanathamsakul N, Siritho S.
    Mult Scler Relat Disord; 2022 Jul 14; 63():103882. PubMed ID: 35598463
    [Abstract] [Full Text] [Related]

  • 14. Predictors of azathioprine and mycophenolate mofetil response in patients with neuromyelitis optica spectrum disorder: A cohort study.
    San Martin DL, Fukuda TG, Nascimento TS, Silva MB, Filho MBP, Forcadela M, Rocchi C, Gibbons E, Hamid S, Huda S, Oliveira-Filho J.
    Mult Scler Relat Disord; 2024 Mar 14; 83():105452. PubMed ID: 38277981
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study.
    Dresser L, Chaar WA, Reder AT, Abuaf AF, Cipriani VP, Javed A.
    Mult Scler Relat Disord; 2023 Jun 14; 74():104718. PubMed ID: 37086634
    [Abstract] [Full Text] [Related]

  • 16. Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).
    Carnero Contentti E, Lopez PA, Patrucco L, Cristiano E, Miguez J, Silva B, Liwacki S, Tkachuk V, Balbuena ME, Vrech C, Deri N, Correale J, Marrodan M, Ysrraelit MC, Fiol M, Leguizamon F, Luetic G, Tavolini D, Mainella C, Zanga G, Burgos M, Hryb J, Barboza A, Lazaro L, Alonso R, Fernández Liguori N, Nadur D, Martinez A, Steinberg J, Carrá A, Alonso Serena M, Rojas JI.
    Mult Scler Relat Disord; 2024 Sep 14; 89():105771. PubMed ID: 39033591
    [Abstract] [Full Text] [Related]

  • 17. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis.
    Yin Z, Qiu Y, Duan A, Fang T, Chen Z, Wu J, Wang Z, Chen G.
    J Neurol; 2023 Jun 14; 270(6):2950-2963. PubMed ID: 36884069
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
    Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R, NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP).
    Mult Scler; 2017 Sep 14; 23(10):1377-1384. PubMed ID: 27885065
    [Abstract] [Full Text] [Related]

  • 19. Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders.
    Kim SH, Hyun JW, Joung A, Park EY, Joo J, Kim HJ.
    Mult Scler; 2017 Dec 14; 23(14):1902-1908. PubMed ID: 28080220
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S.
    Sci Rep; 2020 Oct 07; 10(1):16727. PubMed ID: 33028926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.